terfenadine has been researched along with Lung Neoplasms in 2 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations." | 2.90 | Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. ( Calvo, E; deCastro Carpeno, J; Kim, SW; Laus, G; Lee, JS; Mann, H; Moreno, V; Vishwanathan, K; Weilert, D, 2019) |
| " All of our results confirmed that terfenadine combined with EPI synergistically inhibits the growth and metastatic processes of resistant cells both in vitro and in vivo." | 1.46 | Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. ( An, L; Chu, HX; Fan, YH; Feng, F; Li, DD; Ma, HD; Song, Q; Wang, CL; Zhang, Q; Zhao, QC, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, L | 1 |
| Li, DD | 1 |
| Chu, HX | 1 |
| Zhang, Q | 1 |
| Wang, CL | 1 |
| Fan, YH | 1 |
| Song, Q | 1 |
| Ma, HD | 1 |
| Feng, F | 1 |
| Zhao, QC | 1 |
| Calvo, E | 1 |
| Lee, JS | 1 |
| Kim, SW | 1 |
| Moreno, V | 1 |
| deCastro Carpeno, J | 1 |
| Weilert, D | 1 |
| Laus, G | 1 |
| Mann, H | 1 |
| Vishwanathan, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed[NCT02908750] | Phase 1 | 24 participants (Actual) | Interventional | 2017-03-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for terfenadine and Lung Neoplasms
| Article | Year |
|---|---|
Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Anti-Allergic Agents; Antineoplastic Agents; ATP Binding Casse | 2019 |
1 other study available for terfenadine and Lung Neoplasms
| Article | Year |
|---|---|
Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Bind | 2017 |